Objectives To identify predictive parameters for the progression of skin fibrosis within 1 year in patients with diffuse cutaneous SSc (dcSSc). Methods An observational study using the EUSTAR database was performed. Inclusion criteria were dcSSc, American College of Rheumatology (ACR) criteria fulfilled, modified Rodnan skin score (MRSS) ≥7 at baseline visit, valid data for MRSS at 2nd visit, and available follow-up of 12±2 months. Worsening of skin fibrosis was defined as increase in MRSS >5 points and ≥25% from baseline to 2nd visit. In the univariate analysis, patients with progressive fibrosis were compared with non-progressors, and predictive markers with p<0.2 were included in the logistic regression analysis. The prediction models were then validated in a second cohort. Results A total of 637 dcSSc patients were eligible. Univariate analyses identified joint synovitis, short disease duration (≤15 months), short disease duration in females/patients without creatine kinase (CK) elevation, low baseline MRSS (≤22/51), and absence of oesophageal symptoms as potential predictors for progressive skin fibrosis. In the multivariate analysis, by employing combinations of the predictors, 17 models with varying prediction success were generated, allowing cohort enrichment from 9.7% progressive patients in the whole cohort to 44.4% in the optimised enrichment cohort. Using a second validation cohort of 188 dcSSc patients, short disease duration, low baseline MRSS and joint synovitis were confirmed as independent predictors of progressive skin fibrosis within 1 year resulting in a 4.5-fold increased prediction success rate. Conclusions Our study provides novel, evidence-based criteria for the enrichment of dcSSc cohorts with patients who experience worsening of skin fibrosis which allows improved clinical trial design.

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

GOVONI, Marcello;LO MONACO, Andrea;
2015

Abstract

Objectives To identify predictive parameters for the progression of skin fibrosis within 1 year in patients with diffuse cutaneous SSc (dcSSc). Methods An observational study using the EUSTAR database was performed. Inclusion criteria were dcSSc, American College of Rheumatology (ACR) criteria fulfilled, modified Rodnan skin score (MRSS) ≥7 at baseline visit, valid data for MRSS at 2nd visit, and available follow-up of 12±2 months. Worsening of skin fibrosis was defined as increase in MRSS >5 points and ≥25% from baseline to 2nd visit. In the univariate analysis, patients with progressive fibrosis were compared with non-progressors, and predictive markers with p<0.2 were included in the logistic regression analysis. The prediction models were then validated in a second cohort. Results A total of 637 dcSSc patients were eligible. Univariate analyses identified joint synovitis, short disease duration (≤15 months), short disease duration in females/patients without creatine kinase (CK) elevation, low baseline MRSS (≤22/51), and absence of oesophageal symptoms as potential predictors for progressive skin fibrosis. In the multivariate analysis, by employing combinations of the predictors, 17 models with varying prediction success were generated, allowing cohort enrichment from 9.7% progressive patients in the whole cohort to 44.4% in the optimised enrichment cohort. Using a second validation cohort of 188 dcSSc patients, short disease duration, low baseline MRSS and joint synovitis were confirmed as independent predictors of progressive skin fibrosis within 1 year resulting in a 4.5-fold increased prediction success rate. Conclusions Our study provides novel, evidence-based criteria for the enrichment of dcSSc cohorts with patients who experience worsening of skin fibrosis which allows improved clinical trial design.
2015
B., Maurer; N., Graf; B. A., Michel; U., Muller Ladner; L., Czirjak; C. P., Denton; A., Tyndall; C., Metzig; V., Lanius; D., Khanna; O., Distler; I. H., Arner; M. M., Cerinic; S., Guiducci; U., Walker; G., Lapadula; F., Iannone; R., Becvar; S., Sierakowsky; O. K., Bielecka; M., Cutolo; A., Sulli; G., Valentini; G., Cuomo; S., Vettori; G., Riemekasten; S., Rednic; I., Nicoara; A., Kahan; Y., Allanore; P., Vlachoyiannopoulos; C., Montecucco; R., Caporali; P. E., Carreira; S., Novak; C., Varju; C., Chizzolini; E. J., Kucharz; A., Kotulska; M., Kopec Medrek; M., Widuchowska; F., Cozzi; B., Rozman; C., Mallia; B., Coleiro; A., Gabrielli; D., Farge; A., Hij; P., Airo; R., Hesselstrand; A., Scheja; F., Wollheim; D., Martinovic; A. B., Gurman; Y., Braun Moscovici; Govoni, Marcello; LO MONACO, Andrea; N., Hunzelmann; R., Pellerito; L. M., Bambara; P., Caramaschi; C., Black; N., Damjanov; V. O., Santamaria; S., Heitmann; D., Krasowska; M., Seidel; M., Oleszowsky; H., Burkhardt; A., Himsel; M. J., Salvador; B., Stamenkovic; A., Stankovic; M., Tikly; M. N., Starovoytova; L. P., Ananieva; R., Scorza; M., Engelhart; G., Strauss; H., Nielsen; K., Damgaard; G., Szucs; A. Z., Mendoza; C. d. l. P., Buijdos; W. A., Sifuentes Giraldo; O., Midtvedt; T., Garen; E., Hachulla; D., Launay; G., Valesini; V., Riccieri; R. M., Ionescu; D., Opris; L., Groseanu; F. M., Wigley; C. M., Mihai; R. S., Cornateanu; R., Ionitescu; A. M., Gherghe; M., Gorga; R., Dobrota; M., Bojinca; G., Schett; J. H., Distler; P., Meroni; P., Zeni; L., Mouthon; F. D., Keyser; F. P., Cantatore; A., Corrado; S., Ullman; L., Iversen; M. R., Pozzi; K., Eyerich; R., Hein; E., Knott; J., Szechinski; P., Wiland; M., Szmyrka Kaczmarek; R., Sokolik; E., Morgiel; B., Krummel Lorenz; P., Saar; M., Aringer; C., Gunther; B., Anic; M., Baresic; M., Mayer; S. C., Radominski; C. d. S., Muller; V. F., Azevedo; S., Agachi; L., Groppa; L., Chiaburu; E., Russu; T., Zenone; J., Highton; L., Stamp; P., Chapman; J., O'Donnell; K., Solanki; A., Doube; D., Veale; M., O'Rourke; E., Loyo; M., Li; E., Rosato; S., Pisarri; C. M., Tanaseanu; M., Popescu; A., Dumitrascu; I., Tiglea; R., Chirieac; C., Ancuta; D. E., Furst; S., Kafaja; P. G. d. l. P., Lefebvre; S. R., Rubio; M. V., Exposito; J., Sibilia; E., Chatelus; J. E., Gottenberg; H., Chifflot; I., Litinsky; A., Venalis; I., Butrimiene; P., Venalis; R., Rugiene; D., Karpec; E., Kerzberg; F., Montoya; V., Cosentino
File in questo prodotto:
File Dimensione Formato  
Prediction worsening skin fibrosis in SSc - ARD 2015.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 523.88 kB
Formato Adobe PDF
523.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2039813
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 99
  • ???jsp.display-item.citation.isi??? 94
social impact